skip to content »

Medicine - Mitsiades Lab

Houston, Texas

BCM faculty, staff and trainees are the heart of the organization.
Medicine - Mitsiades Lab
not shown on screen

Selected Publications

  • Mitsiades N. A Road Map to Comprehensive Androgen Receptor Axis Targeting for Castration-Resistant Prostate Cancer. Cancer Res. 2013 Jul 25. [Epub ahead of print]
  • Geng C, He B, Xu L, Barbieri CE, Eedunuri VK, Chew SA, Zimmermann M, Bond R, Shou J, Li C, Blattner M, Lonard DM, Demichelis F, Coarfa C, Rubin MA, Zhou P, O'Malley BW, Mitsiades N. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci U S A. 2013 Apr 4. [Epub ahead of print]
  • Bedoya DJ, Mitsiades N. Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions. Onco Targets Ther. 2013;6:9-18. doi: 10.2147/OTT.S24941. Epub 2013 Jan 3.
  • Mitsiades N, Sung CC, Schultz N, Danila DC, He B, Eedunuri VK, Fleisher M, Sander C, Sawyers CL, Scher HI. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res. 2012 Dec 1;72(23):6142-52. doi: 10.1158/0008-5472.CAN-12-1335. Epub 2012 Sep 12.
  • Bedoya DJ, Mitsiades N. Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2012 Jan;12(1):1-3. doi: 10.1586/era.11.196. No abstract available.
  • Mitsiades N, Pazaitou-Panayiotou K, Aronis KN, Moon HS, Chamberland JP, Liu X, Diakopoulos KN, Kyttaris V, Panagiotou V, Mylvaganam G, Tseleni-Balafouta S, Mantzoros CS. Circulating adiponectin is inversely associated with risk of thyroid cancer: in vivo and in vitro studies. J Clin Endocrinol Metab. 2011 Dec;96(12):E2023-8. doi: 10.1210/jc.2010-1908. Epub 2011 Sep 21.
  • Mitsiades N, Chew SA, He B, Riechardt AI, Karadedou T, Kotoula V, Poulaki V. Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy. Invest Ophthalmol Vis Sci. 2011 Sep 14;52(10):7248-55. doi: 10.1167/iovs.11-7398.
  • Poulaki V, Mitsiades C.S., Kotoula V, Negri J, McMullan C, Miller JW, Marks PA, Mitsiades N. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications. Invest Ophthalmol Vis Sci. 2009 Sep;50(9):4072-9.
  • Kotoula V, Sozopoulos E, Litsiou H, Fanourakis G, Koletsa T, Voutsinas G, Tseleni-Balafouta S, Mitsiades C, Wellmann A, Mitsiades N. Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. Endocr Relat Cancer. 2009 Jun;16(2):565-72.
  • M.G. Ooi, P.J. Hayden, V. Kotoula, D.W. McMillin, E. Charalambous, E. Daskalaki, N.S. Raje, N.C. Munshi, D. Chauhan, T. Hideshima, L. Buon, M. Clynes, P. O'Gorman, P.G. Richardson, C.S. Mitsiades, K.C. Anderson, and N. Mitsiades. Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib. Clin Cancer Res 2009 Dec 1;15(23):7153-60.
  • Mitsiades CS, Hayden P, Kotoula V, McMillin DW, McMullan C, Negri J, Delmore JE, Poulaki V, Mitsiades N. Bcl-2 Overexpression in Thyroid Carcinoma Cells Increases Sensitivity to Bcl-2 Homology 3 Domain Inhibition. J Clin Endocrinol Metab. 2007 Dec;92(12):4845-52.
  • Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMillin D, Miller JW, Mitsiades N. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro. Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4706-19.
  • Mitsiades CS, Negri J, McMullan C, McMillin DW, Sozopoulos E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Poulaki V, Batt D, Mitsiades N. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications. Mol Cancer Ther. 2007 Mar;6(3):1070-8.
  • Mitsiades CS, Kotoula V, Poulaki V, Sozopoulos E, Negri J, Charalambous E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Mitsiades N. Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab. 2006 Sep;91(9):3662-6.
  • Mitsiades CS, Poulaki V, Fanourakis G, Sozopoulos I, McMillin D, Wen Z, Voutsinas G, Tseleni-Balafouta S, Mitsiades N. Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin Cancer Res 2006 Jun 15;12(12):3705-12.
  • Mitsiades CS, Poulaki V, Fanourakis G, Sozopoulos I, McMillin D, Wen Z, Voutsinas G, Tseleni-Balafouta S, Mitsiades N. Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin Cancer Res 2006;12(12):3705-12.
  • Mitsiades N, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003;101(10):4055-62.
  • Mitsiades CS, Mitsiades N, McMullan CJ, Poulaki V, Shringarpure R, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies and solid tumors. Cancer Cell 2004;5(3):221-30.
  • Mitsiades CS, Mitsiades N, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan C, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, Anderson KC. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A 2004; 101(2): 540-5.
  • Mitsiades N, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101(6):2377-80.
  • Mitsiades N, Mitsiades CS, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002; 99: 14374-14379.
  • Mitsiades N, Mitsiades CS, et al. “Apoptotic signaling induced by immunomodulatory thalidomide analogs (IMiDs) in human multiple myeloma cells: therapeutic implications.” Blood 2002;99(12):4525-30.
  • Mitsiades N, Mitsiades CS, Poulaki V, et al. “Biologic sequelae of NF-κB blockade in multiple myeloma: therapeutic applications” Blood 2002;99(11):4079-86.
  • Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP. Intracellular regulation of TRAIL–induced apoptosis in multiple myeloma cells. Blood 2002; 99(6):162-71.
  • Mitsiades, N, et al. Ewing’s Sarcoma Family Tumors Are Sensitive To Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) and express death receptor 4 and death receptor 5. Cancer Research 2001;61(6):2704-12.
  • Mitsiades, N, Yu, W, Poulaki, V, et al. Matrix Metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Research 2001; 61(2):577-581.
  • Mitsiades N, et al. Thyroid carcinoma cells are resistant to Fas-mediated apoptosis but sensitive to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL). Cancer Research 2000;60(15):4122-9.

E-mail this page to a friend